Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting

 Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th
                American Society of Hematology Annual Meeting

PR Newswire

THOUSAND OAKS and SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013

THOUSAND OAKS and SOUTH SAN FRANCISCO, Calif., Nov. 7, 2013 /PRNewswire/ --
Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today
announced that nearly 40 company-sponsored and investigator-sponsored
investigational studies evaluating carfilzomib, a second-generation proteasome
inhibitor, and oprozomib, an oral second-generation proteasome inhibitor in
early development, will be presented at the 55^th American Society of
Hematology (ASH) Annual Meeting and Exposition on December 7-10, 2013 at the
Ernest N. Morial Convention Center in New Orleans, LA.

"We are encouraged by the breadth of data from our Proteasome Inhibitor
franchise being presented this year at ASH, which add to the clinical data of
carfilzomib in combination with other therapies and provide further insight
into the level of response for carfilzomib at a molecular level. Additionally,
data to be presented on oprozomib offer clinical insights instrumental in
driving forward our clinical development program for the compound," said Pablo
Cagnoni, M.D., President of Onyx Pharmaceuticals, Inc. "We remain committed
to bringing innovative therapies to patients in need, and we look forward to
playing a continued role in advancing the scientific understanding of
hematologic malignancies."

Among the presentations are five abstracts from the Proteasome Research and
Integrative Science for Multiple Myeloma – Novel Therapies Program (PRISM
NTP), a global research collaboration between Onyx, investigators at myeloma
centers of excellence and partner companies with novel therapies in
development. "The PRISM program further demonstrates our commitment to
innovation and advancing science," said Homa Yeganegi, Vice President of
Scientific Affairs at Onyx Pharmaceuticals, Inc. "This program is a highly
innovative approach to industry-academia collaboration, bringing together
leaders from the myeloma research community in the service of a common goal:
driving an integrated, personalized approach to the development and delivery
of medicines to patients."

Company-sponsored carfilzomib and oprozomib abstracts:

A Phase 1, Dose-Escalation Study (CHAMPION-1) Investigating Weekly Carfilzomib
in Combination with Dexamethasone for Patients with Relapsed or Refractory
Multiple Myeloma

  oDr. James R. Berenson, Institute for Myeloma & Bone Cancer Research
  oSaturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  oPoster presentation: Myeloma: Therapy, excluding Transplantation: Poster I
  oAbstract # 1934

Association of Treatment Induced Peripheral Neuropathy (TIPN) with Treatment
Patterns and Outcomes in Patients (pts) with Newly Diagnosed Multiple Myeloma
(NDMM)

  oDr. Thomas Martin, University of California, San Francisco
  oSaturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  oPoster presentation: Health Services and Outcomes Research: Poster I
  oAbstract # 1750

Relationship of Serum Free Light Chain Reduction to Best Overall Response in
Phase 2 Single-Agent and Combination Studies of Carfilzomib in Patients with
Relapsed or Relapsed and/or Refractory Multiple Myeloma

  oDr. Ravi Vij, Washington University School of Medicine, St. Louis, MO
  oSaturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  oPoster presentation: Myeloma: Therapy, excluding Transplantation: Poster I
  oAbstract # 1965

Clinical Profile of Single-Agent Modified-Release Oprozomib Tablets in
Patients (Pts) With Hematologic Malignancies: Updated Results From a
Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

  oDr. Irene M. Ghobrial, Dana-Farber Cancer Institute
  oSunday, December 8, 6:30 pm - 8:30 pm CT, Hall G
  oPoster presentation: Myeloma: Therapy, excluding Transplantation: Poster
    II
  oAbstract # 3184

Select Investigator-Sponsored carfilzomib abstracts:

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and
Low-Dose Dexamethasone In Newly Diagnosed, Transplant Eligible Patients With
Multiple Myeloma. A Trial Of The European Myeloma Network

  oDr. Pieter Sonneveld, Erasmus Medical Center, Rotterdam, Netherlands
  oMonday, December 9, 5:15 pm CT, 393-394
  oOral Presentation: Myeloma: Therapy, excluding Transplantation II
  oAbstract # 688

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd)
for Newly Diagnosed Multiple Myeloma

  oDr. Sara Bringhen, Myeloma Unit, Division of Hematology, University of
    Torino, Torino, Italy
  oMonday, December 9, 4:30 pm CT, 393-394
  oOral presentation: Myeloma: Therapy, excluding Transplantation II
  oAbstract # 685

A simple score, based on geriatric assessment, improves prediction of
survival, and risk of serious adverse events in elderly newly diagnosed
multiple myeloma patients

  oDr. Alessandra Larocca, Myeloma Unit, Division of Hematology, University
    of Torino, Torino, Italy
  oMonday, December 9, 5:00 pm CT, 393-394
  oOral presentation: Myeloma: Therapy, excluding Transplantation II
  oAbstract # 687

Phase II Clinical and Correlative Study of Carfilzomib, Lenalidomide, and
Dexamethasone (CRd) Followed by Lenalidomide Extended Dosing (CRD-R) Induces
High Rates of MRD Negativity in Newly Diagnosed Multiple Myeloma (MM) Patients

  oDr. Neha Korde, Multiple Myeloma Section, National Cancer Institute,
    National Institutes of Health
  oMonday, December 9, 3:30 pm CT, 393-394
  oOral presentation: Myeloma: Therapy, excluding Transplantation: Treatment
    Options for Newly Diagnosed Multiple Myeloma Patients
  oAbstract # 538

Serum Heavy-Light Chains (HLC) and Free Light Chains (FLC) As Predictors For
Early CR In Newly Diagnosed Myeloma Patients Treated With Carfilzomib,
Lenalidomide, and Dexamethasone (CRd)

  oDr. Manisha Bhutani, Multiple Myeloma Section, National Cancer Institute,
    National Institutes of Health
  oMonday, December 9, 7:30 pm CT, 393-394
  oOral presentation: Myeloma: Therapy, excluding Transplantation: Advances
    in Multiple Myeloma and Plasma Cell Leukemia
  oAbstract # 762

Phase I/II Dose Expansion of a Multi-Center Trial of Carfilzomib and
Pomalidomide with Dexamethasone (Car-Pom-d) in Patients with
Relapsed/Refractory Multiple Myeloma

  oDr. Jatin Shah, The University of Texas MD Anderson Cancer Center
  oMonday, December 9, 5:45 pm CT, 393-394
  oOral presentation: Myeloma: Therapy, excluding Transplantation II
  oAbstract # 690

Carfilzomib, Rituximab and Dexamethasone (CaRD) is highly active and offers a
neuropathy sparing approach for proteasome-inhibitor based therapy in
Waldenstrom's Macroglobulinemia

  oDr. Steven Peter Treon, Bing Center for Waldenstrom Macroglobulinemia,
    Dana-Farber Cancer Institute
  oMonday, December 9, 6:15 pm CT, 393-394
  oOral presentation: Myeloma: Therapy, excluding Transplantation: Advances
    in Multiple Myeloma and Plasma Cell Leukemia
  oAbstract # 757

PRISM data highlights:

A Novel Bruton's Tyrosine Kinase Inhibitor CC-292 in Combination with the
Proteasome Inhibitor Carfilzomib Impacts Multiple Myeloma Bone Microenviroment
with Resultant Anti-myeloma Activity

  oDr. Homare Eda, MGH Cancer Center, Massachusetts General Hospital
  oMonday, December 9, 5:15 pm CT, 388-390
  oOral presentation: Myeloma: Biology and Pathophysiology, excluding
    Therapy: Bone Marrow Microenvironment and Myeloma Session
  oAbstract # 682

Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor ARRY-520 +
Carfilzomib (Car) in Patients with Relapsed and/or Refractory Multiple Myeloma
(RRMM)

  oDr. Jatin Shah, The University of Texas MD Anderson Cancer Center
  oSaturday, December 7, 5:30 pm - 7:30 pm CT, Hall G
  oPoster presentation: Myeloma: Therapy, excluding Transplantation: Poster I
  oAbstract # 1982

Inhibition of Autophagy by ACY-1215, a Selective HDAC 6 Inhibitor Accelerates
Carfilzomib-Induced Cell Death in Multiple Myeloma

  oDr. Yuko Mishima, Massachusetts General Hospital Cancer Center
  oMonday, December 9, 6:00 pm - 8:00 pm CT, Hall G
  oPoster presentation: Myeloma: Pathophysiology and Pre-Clinical Studies,
    excluding Therapy: Poster III
  oAbstract # 4431

Dual Inhibition of Mcl-1 By The Combination Of Carfilzomib and TG02 In
Multiple Myeloma

  oDr. Katelyn Barnhart, Cancer Biology Graduate Program, Emory University
  oSunday, December 8, 6:30 pm - 8:30 pm CT, Hall G
  oPoster presentation: Myeloma: Pathophysiology and Pre-Clinical Studies,
    excluding Therapy: Poster II
  oAbstract # 3171

Combined Carfilzomib and Selective PI3Kδ Inhibition (TGR1202) Results in
Enhanced Myeloma Cell Apoptosis

  oDr. Claire Torre, Winship Cancer Institute, Emory University
  oSunday, December 8, 6:30 pm - 8:30 pm CT, Hall G
  oPoster presentation: Myeloma: Therapy, excluding Transplantation: Poster
    II
  oAbstract # 3224

About PRISM

PRISM NTP (Proteasome Research and Integrative Science for Multiple Myeloma -
Novel Therapies Program) is a global research collaboration between Onyx,
investigators at myeloma centers of excellence and partner companies with
novel therapies in development. PRISM NTP members come from five centers in
the United States (Dana-Farber Cancer Institute/Partners, Emory, MD Anderson
Cancer Center, Mayo Clinic Scottsdale and Mayo Clinic Rochester) and seven
countries in Europe (France, Germany, Greece, Italy, Netherlands, Spain,
United Kingdom). The program co-chairs are Dr. Kenneth C. Anderson,
Dana-Farber Cancer Institute, Boston and Dr. Jesus San Miguel, University of
Navarra, Spain. There are three working groups led by experts for each area
of focus: molecular profiling, pre-clinical and clinical trial.

About Amgen
Amgen is committed to unlocking the potential of biology for patients
suffering from serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by using tools
like advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics
manufacturing expertise to strive for solutions that improve health outcomes
and dramatically improve people's lives. A biotechnology pioneer since 1980,
Amgen has grown to be the world's largest independent biotechnology company,
has reached millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.

For more information, visit www.amgen.comand follow us on
www.twitter.com/amgen.

About Onyx Pharmaceuticals, Inc.
Based in South San Francisco, California, Onyx Pharmaceuticals, Inc., an Amgen
subsidiary, is a global biopharmaceutical company engaged in the development
and commercialization of innovative therapies for improving the lives of
people with cancer. The company is focused on developing novel medicines that
target key molecular pathways. For more information about Onyx, visit the
company's website at www.onyx.com.

Onyx Pharmaceuticals is on Twitter. Sign up to follow our Twitter feed
@OnyxPharm at http://twitter.com/OnyxPharm.

Amgen Forward Looking Statements
This news release contains forward-looking statements that are based on
management's current expectations and beliefs and are subject to a number of
risks, uncertainties and assumptions that could cause actual results to differ
materially from those described. All statements, other than statements of
historical fact, are statements that could be deemed forward-looking
statements, including estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and
prescriber patterns or practices, reimbursement activities and outcomes and
other such estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC) reports filed
by Amgen, including Amgen's most recent annual report on Form 10-K and any
subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to
Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the
uncertainties and risk factors related to our business. Unless otherwise
noted, Amgen is providing this information as of Oct. 4, 2013, and expressly
disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project. Discovery or identification of new product
candidates or development of new indications for existing products cannot be
guaranteed and movement from concept to product is uncertain; consequently,
there can be no guarantee that any particular product candidate or development
of a new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe and
effective performance of product candidates in humans. The complexity of the
human body cannot be perfectly, or sometimes, even adequately modeled by
computer or cell culture systems or animal models. The length of time that it
takes for us to complete clinical trials and obtain regulatory approval for
product marketing has in the past varied and we expect similar variability in
the future. We develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates that are
derived from relationships may be subject to disputes between the parties or
may prove to be not as effective or as safe as we may have believed at the
time of entering into such relationship. Also, we or others could identify
safety, side effects or manufacturing problems with our products after they
are on the market. Our business may be impacted by government investigations,
litigation and product liability claims. If we fail to meet the compliance
obligations in the corporate integrity agreement between us and the U.S.
government, we could become subject to significant sanctions. We depend on
third parties for a significant portion of our manufacturing capacity for the
supply of certain of our current and future products and limits on supply may
constrain sales of certain of our current products and product candidate
development.

In addition, sales of our products are affected by the reimbursement policies
imposed by third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed
care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. In addition, we compete with other companies with respect to
some of our marketed products as well as for the discovery and development of
new products. We believe that some of our newer products, product candidates
or new indications for existing products, may face competition when and as
they are approved and marketed. Our products may compete against products that
have lower prices, established reimbursement, superior performance, are easier
to administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and technology,
the protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates. We cannot guarantee that we will be able to
produce commercially successful products or maintain the commercial success of
our existing products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant
problems with a product similar to one of our products that implicate an
entire class of products could have a material adverse effect on sales of the
affected products and on our business and results of operations.

The scientific information discussed in this news release related to our
product candidates is preliminary and investigative. Such product candidates
are not approved by the U.S. Food and Drug Administration (FDA), and no
conclusions can or should be drawn regarding the safety or effectiveness of
the product candidates.

Contacts:

Onyx Pharmaceuticals, Inc.
Danielle Bertrand (media)
1-650-266-2114

Amgen
Ashleigh Koss, 1-805-313-6151 (media)
Arvind Sood, 1-805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20131107/LA12955LOGO)

SOURCE Onyx Pharmaceuticals, Inc.; Amgen

Website: http://www.onyx.com
Website: http://www.amgen.com